🇺🇸 FDA
Patent

US 10752607

Polymorphs of N-[(6-cyano-2-fluoro)-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide as kallikrein inhibitors

granted A61KA61K2121/00A61K9/0053

Quick answer

US patent 10752607 (Polymorphs of N-[(6-cyano-2-fluoro)-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide as kallikrein inhibitors) held by KalVista Pharmaceuticals Limited expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
KalVista Pharmaceuticals Limited
Grant date
Tue Aug 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
37
CPC classes
A61K, A61K2121/00, A61K9/0053, A61P, A61P27/02